[Quality of life of women with stress urinary incontinence with or without pollakiuria].
OBJECTIVE
Assess improvement in quality of life using a validated scale in women with urge incontinence or pollakiuria treated with oxybutynine.


METHODS
A prospective open multicentric trial was conducted in 1701 women aged 20 to 60 years (mean 47.6) with the last 2 months. Quality of life was assessed on the Ditrovie scale before and after a 3-month treatment with oxybutynin (7.5 to 15 mg/day).


RESULTS
Patient compliance was good (97%) and side effects rare (8%) (mainly dry mouth). There was a significant symptom improvement (p < or = 0.0001) between day 0 and day 90 after treatment: 48% of the women no longer had incontinence with a safety interval of more than 15 minutes compared with 0.2% prior to treatment; urge incontinence disappeared in 75% of the 81% affected women; 82% of the women had an intermictional interval longer than 2 hours after treatment compared with 33% prior to treatment. There was a significant improvement in the quality of life scores after treatment (p < 0.0001), as assessed by the overall score and subscores (daily life, emotional impact, self-image, sleep, well-being).


CONCLUSIONS
These findings demonstrate the efficacy of oxybutynine in improving urge incontinence and pollakiuria in women, both in terms of symptom relief and quality of life.
Service de Rééducation neurologique, Centre Hospitalier Robert Ballanger, Aulnay-sous-Bois. amarenco@infonie.fr
G
G
Amarenco
P
P
Marquis
C
C
McCarthy
F
F
Richard
D000328:Adult; D005260:Female; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D016896:Treatment Outcome; D014550:Urinary Incontinence, Stress / Q000150:complications / Q000188:drug therapy*; D014555:Urination Disorders / Q000150:complications
D008333:Mandelic Acids; D010276:Parasympatholytics; C005419:oxybutynin
Qualité de vie des femmes souffrant d'impériosité mictionnelle avec ou sans fuites. Etude prospective après traitement par oxybutynine (1701 cas).